MCID: HPT003
MIFTS: 62

Hepatitis a

Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hepatitis a

MalaCards integrated aliases for Hepatitis a:

Name: Hepatitis a 11 75 41 43 14 71
Viral Hepatitis, Type a 11
Viral Hepatitis a 11

Classifications:



External Ids:

Disease Ontology 11 DOID:12549
MeSH 43 D006506
NCIt 49 C3096
SNOMED-CT 68 40468003
ICD10 31 B15.0 B15.9
UMLS 71 C0019159

Summaries for Hepatitis a

MedlinePlus: 41 What is Hepatitis? Hepatitis is inflammation of the liver. Inflammation is swelling that happens when tissues of the body are injured or infected. It can damage your liver. This swelling and damage can affect how well your liver functions. What is hepatitis A? Hepatitis A is a type of viral hepatitis. It causes an acute, or short-term, infection. This means that people usually get better without treatment after a few weeks. Thanks to a vaccine, hepatitis A is not very common in the United States. What causes hepatitis A? Hepatitis A is caused by the hepatitis A virus. The virus spreads through contact with an infected person's stool. This can happen if you: Eat food made by someone who has the virus and did not properly wash their hands after using the bathroom Drink contaminated water or eat foods that were rinsed with contaminated water Have close personal contact with someone who has hepatitis A. This could be through certain types of sex (like oral-anal sex), taking care of someone who is ill, or using illegal drugs with others. Who is at risk for hepatitis A? Although anyone can get hepatitis A, you are at higher risk if you: Travel to developing countries Have sex with someone who has hepatitis A Are a man who has sex with men Use illegal drugs Are experiencing homelessness Live with or care for someone who has hepatitis A Live with or care for a child recently adopted from a country where hepatitis A is common What are the symptoms of hepatitis A? Not everyone with hepatitis A has symptoms. Adults are more likely to have symptoms than children. If you do have symptoms, they usually start 2 to 7 weeks after infection. They can include: Dark yellow urine Diarrhea Fatigue Fever Gray- or clay-colored stools Joint pain Loss of appetite Nausea and/or vomiting Abdominal pain Yellowish eyes and skin, called jaundice The symptoms usually last less than 2 months, although some people can be ill for as long as 6 months. You are at a higher risk of getting a more severe infection from hepatitis A if you also have HIV, hepatitis B, or hepatitis C. What other problems can hepatitis A cause? In rare cases, hepatitis A may lead to liver failure. This is more common in adults over age 50 and in people who have another liver. How is hepatitis A diagnosed? To diagnose hepatitis A, your health care provider may use many tools: A medical history, which includes asking about your symptoms A physical exam Blood tests, including tests for viral hepatitis What are the treatments for hepatitis A? There is no specific treatment for hepatitis A. The best way to recover is to rest, drink plenty of liquids, and eat healthy foods. Your provider may also suggest medicines to help relieve symptoms. In more severe cases, you may need care in a hospital. Can hepatitis A be prevented? The best way to prevent hepatitis A is to get the hepatitis A vaccine. It is also important to have good hygiene, especially washing your hands thoroughly after you go to the bathroom. National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary: Hepatitis a, also known as viral hepatitis, type a, is related to hepatitis and fatty liver disease, and has symptoms including vomiting, fatigue and fever. An important gene associated with Hepatitis a is HAVCR1 (Hepatitis A Virus Cellular Receptor 1), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Levoleucovorin and Atorvastatin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and t cells, and related phenotypes are homeostasis/metabolism and immune system

Disease Ontology: 11 A viral infectious disease that results in inflammation located in liver, has material basis in Hepatitis A virus, which is transmitted by ingestion of contaminated food or water, or transmitted by direct contact with an infected person. The infection has symptom fever, has symptom fatigue, has symptom loss of appetite, has symptom nausea, has symptom vomiting, has symptom abdominal pain, has symptom clay-colored bowel movements, has symptom joint pain, and has symptom jaundice.

Wikipedia: 75 Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral... more...

Related Diseases for Hepatitis a

Diseases in the Hepatitis family:

Hepatitis C Virus Hepatitis a
Hepatitis C Viral Hepatitis
Hepatitis B Hepatitis D
Autoimmune Hepatitis Hepatitis E
Autoimmune Hepatitis Type 2 Autoimmune Hepatitis Type 1

Diseases related to Hepatitis a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1196)
# Related Disease Score Top Affiliating Genes
1 hepatitis 31.8 TNF TICAM1 SERPINA1 IKBKG IFNA1 HAVCR2
2 fatty liver disease 31.7 TNF IL1B IL10 GPT AFP
3 hepatitis e 31.7 TNF TLR3 IL10 IFNG GPT F2
4 viral hepatitis 31.6 SERPINA1 IL4 IFNG IFNA1 GPT F2
5 severe cutaneous adverse reaction 31.5 TNF IFNG GPT CTLA4 CD4
6 autoimmune hepatitis 31.2 TNF IL10 IFNG GPT F2 CTLA4
7 acute kidney failure 31.2 HAVCR1 GPT F2 ALB
8 cholecystitis 31.1 GPT F2 ALB
9 hepatic encephalopathy 31.1 TNF GPT F2 ALB
10 hepatitis b 30.9 TNF TLR3 IFNG IFNA1 GPT F2
11 liver disease 30.9 TNF SERPINA1 IFNA1 GPT F3 F2
12 alcoholic hepatitis 30.9 TNF IL1B IL10 IFNG GPT F2
13 acute pancreatitis 30.8 TNF IL1B IL10 GPT
14 hepatitis c 30.8 TLR3 IL10 IFNG IFNA1 GPT F2
15 typhoid fever 30.8 TNF IL1B IFNG GPT F2 ALB
16 syphilis 30.8 TNF GPT CD4 ALB
17 viral infectious disease 30.7 TNF TLR3 IL4 IL1B IL10 IFNG
18 hepatorenal syndrome 30.7 HAVCR1 GPT F2 ALB AFP
19 acute kidney tubular necrosis 30.7 TNF IL1B HAVCR1 GPT ALB
20 haemophilus influenzae 30.6 TNF IL1B
21 kidney disease 30.6 TNF IL1B IL10 IFNG F2 ALB
22 granulomatous hepatitis 30.5 TNF GPT CTLA4 CD4 ALB
23 pancreatitis 30.5 TNF SERPINA1 IL1B IL10 ALB
24 portal hypertension 30.5 TNF GPT F2 ALB AFP
25 ige responsiveness, atopic 30.5 IL4 IL10 IFNG
26 glomerulonephritis 30.5 TNF IL4 IL1B IL10 ALB
27 gastroenteritis 30.4 TNF IL4 IL1B IL10 IFNG IFNA1
28 interstitial nephritis 30.4 TNF HAVCR1 CD4 ALB
29 hypereosinophilic syndrome 30.4 IL4 IL10 IFNG IFNA1
30 vasculitis 30.4 TNF SERPINA1 IL1B IL10 CTLA4
31 tetanus 30.4 TNF IL4 IL1B IL10 IFNG ALB
32 henoch-schoenlein purpura 30.4 TNF CD4 ALB
33 glucosephosphate dehydrogenase deficiency 30.4 TNF IKBKG GYPA GPT ALB
34 mouth disease 30.4 TLR3 IL10 IFNG IFNA1
35 human cytomegalovirus infection 30.4 TNF IL10 CD4
36 hyperthyroidism 30.4 TNF GPT F2 CTLA4 ALB
37 diphtheria 30.3 TNF IL4 IL1B IFNG IFNA1 ALB
38 encephalitis 30.3 TNF TLR3 IL1B IL10 IFNA1
39 biliary atresia 30.3 IFNG GPT F2 ALB
40 pancytopenia 30.3 IFNG GPT F2 CD4 ALB
41 bowel dysfunction 30.3 TNF IL1B IL10 GPT ALB
42 aplastic anemia 30.3 TNF IL4 IL1B IL10 IFNG CD4
43 anemia, autoimmune hemolytic 30.3 IL10 GYPA CTLA4 CD4
44 mumps 30.3 TNF TLR3 IL1B IL10 IFNG IFNA1
45 drug-induced hepatitis 30.3 TNF GPT F2 CD4 ALB AFP
46 neuromyelitis optica 30.3 IL4 IL1B IFNA1
47 wilson disease 30.3 SERPINA1 GPT F2 ALB
48 inflammatory bowel disease 1 30.3 TNF IL1B IL10
49 graft-versus-host disease 30.2 TNF IL10 IFNG
50 alcoholic liver cirrhosis 30.2 TNF IL1B GPT F2 ALB AFP

Graphical network of the top 20 diseases related to Hepatitis a:



Diseases related to Hepatitis a

Symptoms & Phenotypes for Hepatitis a

Symptoms:

11
  • vomiting
  • fatigue
  • fever
  • jaundice
  • abdominal pain
  • nausea
  • loss of appetite
  • joint pain
  • clay-colored bowel movements

UMLS symptoms related to Hepatitis a:


nausea and vomiting; constipation; fever; abdominal pain; pruritus; diarrhea; dyspepsia; icterus; heartburn; gastrointestinal gas

GenomeRNAi Phenotypes related to Hepatitis a according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.14 AFP ALB CD4 CTLA4 F2 F3
2 no effect GR00402-S-2 10.14 ALB CD4 CTLA4 F2 F3 GYPA

MGI Mouse Phenotypes related to Hepatitis a:

45 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 AFP ALB CD4 CTLA4 F2 F3
2 immune system MP:0005387 10.22 ALB CD4 CTLA4 F2 F3 HAVCR1
3 neoplasm MP:0002006 10.21 AFP ALB F3 IFNG IKBKG IL10
4 normal MP:0002873 10.19 ALB CTLA4 F2 F3 IFNA1 IFNG
5 endocrine/exocrine gland MP:0005379 10.17 AFP ALB CD4 CTLA4 F2 IFNG
6 cardiovascular system MP:0005385 10.15 ALB CTLA4 F2 F3 HAVCR2 IFNG
7 liver/biliary system MP:0005370 10.13 AFP ALB CTLA4 IFNG IKBKG IL10
8 digestive/alimentary MP:0005381 10.1 ALB CD4 CTLA4 F2 IFNG IKBKG
9 hematopoietic system MP:0005397 10.06 CD4 CTLA4 F2 F3 GYPA HAVCR1
10 respiratory system MP:0005388 10 CTLA4 F2 F3 HAVCR1 IFNA1 IFNG
11 mortality/aging MP:0010768 9.86 ALB CD4 CTLA4 F2 F3 HAVCR1
12 integument MP:0010771 9.32 CD4 CTLA4 F2 F3 IFNG IKBKG

Drugs & Therapeutics for Hepatitis a

Drugs for Hepatitis a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 462)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Atorvastatin Approved Phase 4 134523-00-5 60823
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184 444254
4
Aluminium phosphate Approved, Investigational Phase 4 7784-30-7
5
Framycetin Approved, Experimental, Vet_approved Phase 4 1404-04-2, 119-04-0, 3947-65-7 413349 8378
6
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
7
Pyrazinamide Approved, Investigational Phase 4 98-96-4 1046
8
Rifampicin Approved Phase 4 13292-46-1 135512673 5381226 135900090
9
Aluminum sulfate Approved Phase 4 10043-01-3
10
Milk thistle Approved, Experimental, Investigational Phase 4 65666-07-1
11
Aluminum hydroxide Approved, Investigational Phase 4 21645-51-2
12
Racivir Approved, Investigational Phase 4 143491-57-0, 143491-54-7 60877
13
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
14
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
15
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
16
Simethicone Approved Phase 4 8050-81-5
17
Metformin Approved Phase 4 1115-70-4, 657-24-9 4091
18
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8
19
Nevirapine Approved Phase 4 129618-40-2 4463
20
Zidovudine Approved Phase 4 30516-87-1 35370
21
Colchicine Approved Phase 4 64-86-8 2833 6167
22
Iron Approved Phase 4 7439-89-6 29936
23
Chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
24
Rituximab Approved Phase 4 174722-31-7
25
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
26
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
27
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
28
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
29
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
30
Nelfinavir Approved Phase 4 159989-64-7 64143
31
Losartan Approved Phase 4 114798-26-4 3961
32
Cobicistat Approved Phase 4 1004316-88-4 24950485 25151504
33
Elvitegravir Approved Phase 4 697761-98-1 23083982 5277135
34
Azathioprine Approved Phase 4 446-86-6 2265
35
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
36
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
37
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
38
Ezetimibe Approved Phase 4 163222-33-1 150311
39
Pancrelipase Approved, Investigational Phase 4 53608-75-6 8519
40
Parathyroid hormone Approved, Investigational Phase 4 9002-64-6
41
Calcium carbonate Approved, Investigational Phase 4 471-34-1
42
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
43
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
44
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
45
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7, 53152-21-9 644073 40400
46
Methadone Approved Phase 4 76-99-3, 1095-90-5 4095
47
Interferon alfacon-1 Approved, Investigational Phase 4 118390-30-0
48
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
49
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
50
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999

Interventional clinical trials:

(show top 50) (show all 2744)
# Name Status NCT ID Phase Drugs
1 Effectiveness of Booster Vaccination With 1 or 2 Doses of Hepatitis A Vaccine Among HIV-infected Patients During an Ongoing Outbreak in Taiwan Unknown status NCT03855176 Phase 4 Vaqta Injectable Product
2 Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children Unknown status NCT03330171 Phase 4
3 Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time Unknown status NCT01926860 Phase 4
4 Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines Unknown status NCT03231605 Phase 4
5 A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Unknown status NCT01965418 Phase 4 Fufang Biejia Ruangan Tablet;Placebo
6 Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B Unknown status NCT01906580 Phase 4 Peg-IFNα-2a;Entecavir
7 The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B Unknown status NCT03349008 Phase 4 Entecavir;Magnesium Isoglycyrrhizinate;Diammonium Glycyrrhizinate;Magnesium Isoglycyrrhizinate Placebo;Diammonium Glycyrrhizinate Placebo
8 Prospective, Multicenter, Randomized, and Comparative Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes Unknown status NCT04584242 Phase 4 gluconon tab 15mg;suganon tab 5mg
9 The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates Unknown status NCT02764671 Phase 4
10 The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
11 Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis Unknown status NCT02971306 Phase 4 standard medical therapy;G-CSF;n-Acetylcysteine
12 Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase Unknown status NCT01833611 Phase 4 Entecavir;placebo
13 Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients Unknown status NCT03332329 Phase 4 Entecavir;Granulocyte Macrophage Colony Stimulating Factor;Y peginterferon alfa-2b;HBV vaccine
14 Granulocyte Colony Stimulating Factor in Alcoholic Hepatitis Unknown status NCT03703674 Phase 4 GCSF
15 Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2) Unknown status NCT02768545 Phase 4 Ezetimibe
16 Efficacy of Antiviral Therapy With Lamivudine or Entecavir After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
17 Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial. Unknown status NCT02108301 Phase 4 tacrolimus-cyclosporine A
18 Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues Unknown status NCT02982837 Phase 4 PEG-IFN & Nucleos(t)tide analogues;Nucleos(t)tide analogues
19 Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial Unknown status NCT01907230 Phase 4 Entecavir
20 A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR) Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
21 Entecavir for Patients With Decompensated HBV-Related Cirrhosis:a Prospective Randomized Controlled Trial Unknown status NCT00663182 Phase 4 Entecavir
22 Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3) Unknown status NCT03888729 Phase 4 sofosbubir/velpatasvir;sofosbubir/velpatasvir/voxilaprevir
23 The Optimizing Treatment of Peginterferon Alpha in Chronic Hepatitis B Patients With Low Level HBsAg(I-Cure-3X) Unknown status NCT03801538 Phase 4 Peginterferon Alfa;Nucleoside Analog (Substance)
24 Localized on -Site Testing and Treatment of Hepatitis C in Homeless Persons in South London: a Pilot Non-randomised Phase 4 Interventional Clinical Trial of Grazoprevir and Elbasvir ± Ribavirin in Participants With Genotype 1a, 1b or 4 to Measure Efficacy and Adherence to Treatment in a Homeless Population Unknown status NCT03797066 Phase 4 ZEPATIER 50Mg-100Mg Tablet
25 Screening for Hepatitis C and Hepatitis B in Inpatients: A Toronto Viral Hepatitis Care Network (VIRCAN) Collaboration Unknown status NCT04620226 Phase 4
26 Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02745132 Phase 4
27 Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy Unknown status NCT02638233 Phase 4 Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
28 Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues Unknown status NCT01911156 Phase 4 Continue NA treatment;Discontinue NA Treatment
29 Investigator Initiated Study of Thymosin in HBV-related HCC Unknown status NCT02281266 Phase 4 thymalfasin;nucleoside analog (suggest to use entecavir)
30 Maternal Screening and Antiviral Therapy in Pregnant Women to Reduce Mother-to-infant Transmission of Hepatitis B Virus Unknown status NCT03695029 Phase 4 Tenofovir Alafenamide
31 Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study Unknown status NCT02639585 Phase 4 Daclinza and Sunvepra
32 A Randomized, Open Label, Phase IV, Multicenter Study for Efficacy and Safety of Lamivudine Versus Entecarvir Therapy in HBV-related Advanced Liver Disease Patients With High Viral Load and Normal or Slightly Elevated Transaminase Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
33 A Randomized, Double Blind Controlled Trial to Evaluate the Therapeutic Effect of Telbivudine With or Without Prednisolone Priming in Patients With Chronic Hepatitis B Unknown status NCT00778596 Phase 4 Prednisolone;Placebo priming
34 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline
35 Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor Unknown status NCT02973646 Phase 4 Entecavir or Tenofovir;Peginterferon Alfa-2B
36 A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
37 A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B Unknown status NCT03357822 Phase 4 Pegylated interferon;Entecavir;Tenofovir disoproxil fumarate
38 Efficacy and Safety of Switching to Tenofovir Alafenamide for Chronic Hepatitis B Patients With Advanced Fibrosis and Partial Virologic Responses to Oral Nucleos(t)Ide Analogues Unknown status NCT03798119 Phase 4 Tenofovir Alafenamide
39 A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection Unknown status NCT02759861 Phase 4 harvoni
40 The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg Unknown status NCT02745704 Phase 4 Peginterferon alfa
41 Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Unknown status NCT02588937 Phase 4 EntecaBell ODT. 0.5mg;Baraclude Tab. 0.5mg
42 The Effects of Preventive Versus on Demand Nutritional Advice and Support on the Nutritional Status of Patients During Antiviral Therapy for Hepatitis C A Randomized, Multi Center Trial Unknown status NCT00841243 Phase 4
43 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
44 Analysis of Proximal Renal Tubular Function of "Real World" Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF Unknown status NCT02957994 Phase 4 Tenofovir alafenamide fumarate
45 Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B Unknown status NCT01925820 Phase 4 Pegasys&Entecavir
46 Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant Unknown status NCT03359746 Phase 4 Grazoprevir/Elbasvir
47 The Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4 Unknown status NCT03743727 Phase 4 Combined therapy LDV and SOF
48 Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine Unknown status NCT02774837 Phase 4 Tenofovir disoproxil;Telbivudine
49 Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C Unknown status NCT03022006 Phase 4 elbasvir, grazoprevir
50 A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta Unknown status NCT00117533 Phase 4 pegylated IFN alfa-2b plus ribavirin

Search NIH Clinical Center for Hepatitis a

Cochrane evidence based reviews: hepatitis a

Genetic Tests for Hepatitis a

Anatomical Context for Hepatitis a

Organs/tissues related to Hepatitis a:

FMA: Liver
MalaCards : Liver, Kidney, T Cells, Skin, Placenta, Myeloid, Bone Marrow

Publications for Hepatitis a

Articles related to Hepatitis a:

(show top 50) (show all 13170)
# Title Authors PMID Year
1
Hepatitis A virus seroprevalence among children and adolescents in a high-burden HIV setting in urban South Africa. 62 41
36450802 2022
2
Hepatitis A and hepatitis B infection risk among employees at schools for disabled pupils. 62 41
36424401 2022
3
Resolved hepatitis B infection in patients receiving immunosuppressive therapy: Monitor versus prophylaxis against viral reactivation. 41
36451458 2022
4
Live enteroviruses, but not other viruses, detected in human pancreas at the onset of type 1 diabetes in the DiViD study. 62
35953727 2022
5
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension. 62
35973578 2022
6
Endemicity change of hepatitis A infection necessitates vaccination in food handlers: An Indian perspective. 62
33595412 2022
7
Calcineurin Inhibitors in the Treatment of Adult Autoimmune Hepatitis: A Systematic Review. 62
36381101 2022
8
Seroprevalence of Hepatitis A, B and C Among a Sample of Refugees in Egypt: An Exploratory Survey. 62
36107333 2022
9
Comparative transcriptome reveals the effect of IFITM1 on differential resistance to duck hepatitis A virus genotype 3 in Pekin ducks. 62
36130655 2022
10
The impact of different IPV-OPV sequential immunization programs on hepatitis A and hepatitis B vaccine efficacy. 62
35044877 2022
11
Hepatocellular Injury in Children Treated for Rifampicin-resistant Tuberculosis: Incidence, Etiology and Outcome. 62
36102699 2022
12
Implementation of EACS vaccination recommendations among people living with HIV. 62
35522383 2022
13
Treatment of hospital wastewater by electron beam technology: Removal of COD, pathogenic bacteria and viruses. 62
36055595 2022
14
Incidence trends of acute viral hepatitis caused by four viral etiologies between 1990 and 2019 at the global, regional and national levels. 62
36214561 2022
15
[(Rare) infectious hepatitis as an important differential diagnosis of unclear hepatopathy]. 62
36456751 2022
16
Treatment effects of phosphorylated Chrysanthemum indicum polysaccharides on duck viral hepatitis by protecting mitochondrial function from oxidative damage. 62
36395693 2022
17
A case of hepatitis induced by herbal medicine in non-small cell lung cancer patient treated by a combination of immunotherapy and chemotherapy. 62
35484834 2022
18
Quality of antibody responses by adults and young children to 13-valent pneumococcal conjugate vaccination and Streptococcus pneumoniae colonisation. 62
36210249 2022
19
Epidemiology and Risk Factors for Acute Viral Hepatitis in Bangladesh: An Overview. 62
36422336 2022
20
Modeling long-term persistence after 8 years of hepatitis B booster vaccination in 5- to 15-year-old children. 62
35507912 2022
21
Impact of a Targeted Intervention on Hepatitis C Care Among African Americans With Serious Mental Illness. 62
35473365 2022
22
Attractive and healthy-looking male faces do not show higher immunoreactivity. 62
36319732 2022
23
Nonlytic Quasi-Enveloped Hepatovirus Release Is Facilitated by pX Protein Interaction with the E3 Ubiquitin Ligase ITCH. 62
36286484 2022
24
The Association of Glycemic Index, Glycemic Load, and Daily Carbohydrates Intake with the Risk of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. 62
36411493 2022
25
A link between severe hepatitis in children and adenovirus 41 and adeno-associated virus 2 infections. 62
36367762 2022
26
Medical screening tests and vaccination among hospital-based physicians in Israel. 62
36357854 2022
27
Wide Variability in Documentation of Sexual Orientation, Gender Identity, and Preventive Health Screenings in a Diverse Sample of U.S. Community Health Centers. 62
35772015 2022
28
Macrophage Depletion Reactivates Fecal Virus Shedding following Resolution of Acute Hepatitis A in Ifnar1-/- Mice. 62
36354341 2022
29
Hepatitis A in the Eastern Mediterranean Region: a comprehensive review. 62
35617508 2022
30
A combined inactivated cholera and hepatitis A vaccine-induced potent protective immunity in a mouse model. 62
36269328 2022
31
Decreasing Trends in the Incidence of Age- and Sex-specific Hepatitis A Virus Infection in Hunan Province, China, from 2004-2020: A Joinpoint Analysis. 62
36443258 2022
32
Crystal digital RT-PCR for the detection and quantification of norovirus and hepatitis A virus RNA in frozen raspberries. 62
36055105 2022
33
Monkeypox, severe hepatitis A, and syphilis in an HIV returning traveler from Spain to Romania. 62
36089283 2022
34
2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: A too early endpoint? 62
35716845 2022
35
Ethnic differences in hepatitis A and E virus seroprevalence in patients attending the Emergency Department, Paramaribo, Suriname. 62
36353973 2022
36
Seroepidemiology of hepatitis A virus infection in Japan: An area of very low endemicity. 62
36333781 2022
37
HIV PrEP and viral hepatitis: a unique opportunity for integration. 62
36332650 2022
38
An electronic medical record-based intervention to improve hepatitis A vaccination rates in the emergency department during a regional outbreak. 62
36410781 2022
39
Shifting Hepatitis A Epidemiology Requires Renewed Vaccination Efforts. 62
36346409 2022
40
A custom hepatitis A virus assay for whole-genome sequencing. 62
36375537 2022
41
WHO Backs Single Dose of Hepatitis A Vaccine in Some Cases. 62
36378201 2022
42
Duck hepatitis A virus prevalence in mainland China between 2009 and 2021: A systematic review and meta-analysis. 62
35964373 2022
43
Portosystemic shunt, a rare cause of neonatal cholestatic hepatitis. A case report. 62
36378196 2022
44
A high-dimensional cytometry atlas of peripheral blood over the human life span. 62
36218032 2022
45
Prevalence of enteric viruses in wastewater in Egypt after the COVID-19 pandemic. 62
36448616 2022
46
Adult Vaccination. 62
36379499 2022
47
Exotic viral hepatitis: A review on epidemiology, pathogenesis, and treatment. 62
35817222 2022
48
Clinical features and outcomes of opsoclonus myoclonus ataxia syndrome. 62
36155293 2022
49
Effect of an Integrated Transplantation Mental Health Program on Alcohol Relapse After Liver Transplantation for Severe Alcoholic Hepatitis: A Single-Center Prospective Study. 62
36411097 2022
50
RIPK3 modulates sarcoma through immune checkpoint HAVCR2. 62
36238358 2022

Variations for Hepatitis a

Expression for Hepatitis a

Search GEO for disease gene expression data for Hepatitis a.

Pathways for Hepatitis a

Pathways related to Hepatitis a according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.91 TNF TLR3 TICAM1 SERPINA1 IL4 IL1B
2
Show member pathways
13.65 TNF IL4 IL1B IL10 IKBKG IFNG
3
Show member pathways
13.57 TNF IL4 IL1B IL10 IKBKG IFNG
4
Show member pathways
13.42 TNF TLR3 IL4 IL1B IL10 IKBKG
5
Show member pathways
13.34 TNF IL4 IL1B IL10 IKBKG IFNG
6
Show member pathways
12.89 IFNA1 IKBKG IL1B TICAM1 TLR3 TNF
7
Show member pathways
12.7 TNF IL1B IKBKG IFNG CD4
8
Show member pathways
12.67 TNF IL4 IL1B IL10 IFNG IFNA1
9
Show member pathways
12.55 TNF IL1B IL10 IKBKG IFNG F2
10
Show member pathways
12.53 TNF TLR3 TICAM1 IL1B IKBKG IFNA1
11
Show member pathways
12.49 TLR3 TICAM1 IKBKG IFNG IFNA1
12
Show member pathways
12.45 TLR3 TICAM1 IL1B IKBKG IFNA1
13
Show member pathways
12.45 TNF IL4 IL1B IKBKG IFNG
14
Show member pathways
12.39 SERPINA1 F2 ALB AFP
15
Show member pathways
12.35 TNF TLR3 TICAM1 IL1B IKBKG IFNG
16 12.14 TNF IL4 IL1B IL10 IFNG
17 12.04 TNF IL4 IL1B IFNG
18
Show member pathways
12.02 IL4 IL1B IFNG CD4
19 12 TNF IL4 IL1B IL10
20 11.95 TNF IL4 IL10 IFNG GYPA CD4
21 11.92 TNF TLR3 TICAM1 IL4 IL1B IL10
22
Show member pathways
11.89 TLR3 IL4 IL1B IFNG CD4
23
Show member pathways
11.88 TNF IL4 IL10 IKBKG IFNG CTLA4
24
Show member pathways
11.85 TNF TLR3 IL1B IL10 IFNG CD4
25 11.82 TLR3 IL10 IFNG CD4
26
Show member pathways
11.8 F3 IFNG IKBKG IL1B TNF
27 11.79 TNF IL4 IL10 IFNG
28 11.78 IL4 IFNG AFP
29 11.77 IL4 IL1B IFNG CD4
30 11.77 CTLA4 IFNG IL10 IL1B IL4 TNF
31
Show member pathways
11.75 TNF IL4 IFNG CTLA4
32 11.73 IL4 IL10 IFNG
33 11.72 IL1B IL4 SERPINA1 TNF
34 11.72 TNF IL1B IL10 IFNG CD4
35
Show member pathways
11.69 TNF IL1B IFNG
36 11.68 TNF IL10 IKBKG
37 11.68 TNF IL1B IL10
38
Show member pathways
11.68 TNF IL4 IL10 IFNG
39 11.64 TNF IL4 IL1B IL10 IFNG CD4
40 11.59 TNF IL10 HAVCR2
41 11.56 TNF IL1B IFNG
42 11.56 IL4 IL10 IFNG CD4
43 11.55 TNF IL1B IL10
44 11.53 IFNG IL1B TNF
45 11.52 TNF TLR3 TICAM1 IKBKG
46
Show member pathways
11.51 F2 ALB AFP
47 11.51 TNF IL4 IL10 IKBKG IFNG CD4
48 11.44 CD4 F2 F3 IL10
49
Show member pathways
11.43 TNF IL10 IFNG
50 11.41 TNF IL1B IL10

GO Terms for Hepatitis a

Cellular components related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.72 TNF TLR3 SERPINA1 IL4 IL1B IL10

Biological processes related to Hepatitis a according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 10.43 TNF TLR3 TICAM1 IL4 IL1B IFNG
2 inflammatory response GO:0006954 10.39 TNF TLR3 TICAM1 IL1B IKBKG HAVCR2
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.27 TNF TLR3 TICAM1 IL1B IKBKG
4 positive regulation of inflammatory response GO:0050729 10.24 IFNG IL1B TLR3 TNF
5 cellular response to lipopolysaccharide GO:0071222 10.24 TNF TICAM1 IL1B IL10 HAVCR2
6 positive regulation of tumor necrosis factor production GO:0032760 10.23 TLR3 TICAM1 IFNG HAVCR2
7 response to virus GO:0009615 10.21 TNF TLR3 IKBKG IFNG
8 positive regulation of type II interferon production GO:0032729 10.2 HAVCR2 IL1B TLR3 TNF
9 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.18 HAVCR2 IL1B TLR3 TNF
10 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.18 TNF TLR3 TICAM1 IL1B IKBKG CD4
11 negative regulation of T cell proliferation GO:0042130 10.16 IL10 HAVCR2 CTLA4
12 positive regulation of interleukin-8 production GO:0032757 10.16 TNF TLR3 IL1B F3
13 lipopolysaccharide-mediated signaling pathway GO:0031663 10.15 TNF TICAM1 IL1B
14 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.14 F2 IL10 TNF
15 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 10.14 TNF IL1B IKBKG
16 response to exogenous dsRNA GO:0043330 10.14 TLR3 TICAM1 IFNA1
17 positive regulation of interleukin-6 production GO:0032755 10.13 IFNG IL1B TICAM1 TLR3 TNF
18 positive regulation of nitric oxide biosynthetic process GO:0045429 10.06 TNF TICAM1 IL1B IFNG
19 positive regulation of membrane protein ectodomain proteolysis GO:0051044 10.02 TNF IL1B IFNG
20 positive regulation of heterotypic cell-cell adhesion GO:0034116 10.01 TNF IL1B IL10
21 macrophage activation involved in immune response GO:0002281 10 HAVCR2 IFNG TICAM1
22 immune response GO:0006955 10 TNF TLR3 IL4 IL1B IL10 IKBKG
23 astrocyte activation GO:0048143 9.99 IFNG IL1B TNF
24 positive regulation of mononuclear cell migration GO:0071677 9.98 TNF IL4
25 negative regulation of cytokine production involved in immune response GO:0002719 9.98 TNF IL10
26 positive regulation of fever generation GO:0031622 9.98 TNF IL1B
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.97 IL4 IL10 IFNG
28 microglial cell activation GO:0001774 9.97 TNF TLR3 IL4 IFNG
29 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.97 TNF TLR3 TICAM1 IL1B IKBKG
30 regulation of isotype switching GO:0045191 9.96 IL4 IL10
31 sequestering of triglyceride GO:0030730 9.95 TNF IL1B
32 toll-like receptor 3 signaling pathway GO:0034138 9.95 TNF TLR3 HAVCR2
33 positive regulation of nitrogen compound metabolic process GO:0051173 9.93 TNF IFNG
34 negative regulation of myeloid dendritic cell activation GO:0030886 9.92 IL10 HAVCR2
35 positive regulation of vitamin D biosynthetic process GO:0060557 9.91 TNF IFNG
36 chronic inflammatory response to antigenic stimulus GO:0002439 9.91 TNF IL10
37 hemostasis GO:0007599 9.81 SERPINA1 F3 F2
38 MyD88-independent toll-like receptor signaling pathway GO:0002756 9.79 TLR3 TICAM1
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.73 IFNG IL1B TNF
40 positive regulation of cytokine production GO:0001819 9.61 TNF TLR3 IL1B IL10 IFNG HAVCR2
41 positive regulation of chemokine production GO:0032722 9.36 TNF TLR3 TICAM1 IL1B IFNG HAVCR2

Molecular functions related to Hepatitis a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.4 TNF IL4 IL1B IL10 IFNG IFNA1

Sources for Hepatitis a

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....